The results of the prothrombin time assay of plasma confirmed the high biocompatibility of CQDs, and the inhibition yield for MCF-7 and MDA-MB-231 cancer cells were up to 80% and 82%, respectively, which confirmed the high capability of CQDs as cancer inhibitors [165]. The gene discussed is F2; the disease is cancer.